The civic record
Read. Follow. Verify.Kentucky Voids Specific Addiction Medication Rules and Bars Licensing Boards from Restricting FDA-Approved Treatments
Last action · January 14, 2026: to Health Services (H)Sponsors: Lisa Willner and 11 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
AN ACT relating to administrative regulations for medications for substance use disorder and declaring an emergency.
Medical, dental, nursing, and pharmacy professionals face new statutory limits on state oversight regarding the prescription and dispensing of specific addiction treatment medications.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
State Board of Medical Licensure
The board is prohibited from promulgating administrative regulations that restrict or limit FDA-approved Schedule III, IV, or V medications for substance use disorder.
Kentucky Board of Dentistry
The board is prohibited from promulgating administrative regulations that restrict or limit FDA-approved Schedule III, IV, or V medications for substance use disorder.
Kentucky Board of Nursing
The board is prohibited from promulgating administrative regulations that restrict or limit FDA-approved Schedule III, IV, or V medications for substance use disorder.
Kentucky Board of Pharmacy
The board is prohibited from promulgating administrative regulations that restrict or limit FDA-approved Schedule III, IV, or V medications for substance use disorder.
Key Facts
- Declares administrative regulations 201 KAR 9:270 and 201 KAR 20:065, concerning buprenorphine products and APRN standards, to be deficient, null, void, and unenforceable.
- Prohibits administrative bodies from promulgating administrative regulations identical or substantially the same as the voided regulations.
- Bars the State Board of Medical Licensure from promulgating regulations that restrict or limit buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or other FDA-approved Schedule III, IV, or V substance use disorder medications.
- Bars the Kentucky Board of Dentistry from promulgating regulations that restrict or limit buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or other FDA-approved Schedule III, IV, or V substance use disorder medications.
Show all 7 facts
- Bars the Kentucky Board of Nursing from promulgating regulations that restrict or limit buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or other FDA-approved Schedule III, IV, or V substance use disorder medications.
- Bars the Kentucky Board of Pharmacy from promulgating regulations that restrict or limit buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or other FDA-approved Schedule III, IV, or V substance use disorder medications.
- Clarifies that licensing boards retain the authority to enforce broader controlled substance regulations that apply across schedules, such as specific existing rules like 201 KAR 9:260, 201 KAR 8:540, and 201 KAR 20:057.
Frequently Asked Questions
Which specific administrative regulations are voided by this bill?
Does this bill prevent licensing boards from regulating all controlled substances?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in House committee.
Procedural history
2 actions- Jan 14, 2026HouseCommitteeto Health Services (H)
- Jan 7, 2026HouseIntroducedintroduced in House to Committee on Committees (H)
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 7 more sponsors
Connected Entities
Sources
apps.legislature.ky.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy65Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz40Current news / social attention level
Publisher tools